|
|
Volumn 72, Issue 20, 2012, Pages 5151-5158
|
|
Why RECIST works and why it should stay - Counterpoint
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AXITINIB;
BEVACIZUMAB;
CABAZITAXEL;
CETUXIMAB;
CRIZOTINIB;
DOCETAXEL;
ERIBULIN;
ERLOTINIB;
EVEROLIMUS;
FULVESTRANT;
GEMCITABINE;
IMATINIB;
IPILIMUMAB;
IXABEPILONE;
LAPATINIB;
OXALIPLATIN;
PACLITAXEL;
PANITUMUMAB;
PAZOPANIB;
PEMETREXED;
PLACEBO;
SIPULEUCEL T;
SORAFENIB;
SUNITINIB;
TEMSIROLIMUS;
TOPOTECAN;
TRASTUZUMAB;
VANDETANIB;
BREAST TUMOR;
CANCER GROWTH;
CANCER SURVIVAL;
CLINICAL ASSESSMENT TOOL;
COLORECTAL TUMOR;
DRUG MECHANISM;
GASTROESOPHAGEAL TUMOR;
GASTROINTESTINAL STROMAL TUMOR;
GASTROINTESTINAL TUMOR;
GLIOBLASTOMA;
HEAD AND NECK SQUAMOUS CELL CARCINOMA;
HUMAN;
KIDNEY TUMOR;
LIVER CELL CARCINOMA;
LUNG NON SMALL CELL CANCER;
MELANOMA;
MESOTHELIOMA;
OVARY TUMOR;
PANCREAS TUMOR;
PHASE 1 CLINICAL TRIAL (TOPIC);
PHASE 2 CLINICAL TRIAL (TOPIC);
PHASE 3 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
PROSTATE TUMOR;
REPONSE EVALUATION CRITERIA IN SOLID TUMOR;
REVIEW;
SOLID TUMOR;
TREATMENT RESPONSE;
TUMOR VOLUME;
UTERINE CERVIX TUMOR;
VALIDITY;
CLINICAL TRIALS AS TOPIC;
DISEASE PROGRESSION;
EVIDENCE-BASED MEDICINE;
HUMANS;
NEOPLASMS;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 84867557339
PISSN: 00085472
EISSN: 15387445
Source Type: Journal
DOI: 10.1158/0008-5472.CAN-12-0733 Document Type: Review |
|
Times cited : (28)
|
|
References (0)
|
